Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.

Breast Cancer Clinical Trial

Official title:

A Multi-center, 2-arm Observational Study Exploring the Role of the Gut and Tumor Microbiome in the Differential Immune Profile of Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer (Arm-1).

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06126003
• Other study ID #: BIOMAP-201
• Status: Recruiting
• Start date: December 1, 2023
• Est. completion date: January 13, 2025

Study information

• Verified date: April 2024
• Source: BioCorteX Inc
• Contact: Christine Reed
• Phone: 800-739-4137
• Email: christine.reed[@]tempus.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this research study is to collect samples of blood and stool and analyse primary tumor from participants with breast cancer to see how the bacteria in the body affect cancer and how well it responds to treatment. By comparing samples and data from multiple participants with breast cancer, it may be possible to identify how a person's gut health and tumor microenvironment affects how they respond to certain cancer treatments.

Description:

After being informed about the study and potential risks, all participants giving written informed consent will provide a pre-treatment stool sample looking at the gut microbiome, primary tumor sequencing analysis to infer tumor microbiome, and a blood sample for the CyTOF whole blood Immune Profile. Blood tests (full blood count, renal profile, liver profile, C-reactive protein), medical history, concomitant medications, and the Eastern Cooperative Oncology Group (ECOG) performance level will be obtained through a mixture of self-reported and data collated from the electronic health record (EHR). Two food frequency questionnaires will be given to participants to complete at two timepoints: at screening and at end of study. There are 5 study visits. Participants will provide a stool sample for gut microbiome sequencing at weeks 2 and 4 of the study. During the Week 6 visit, participants will provide final stool samples for gut microbiome analysis, and a blood sample for CyTOF whole blood Immune Profile. ECOG performance status and adverse event data will be obtained from EHR.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: January 13, 2025
• Est. primary completion date: December 13, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

Arm-1: Early stage (II-III), locally advanced or advanced ER-positive and HER2-negative Breast Cancer

1. Signed, written, voluntary, and informed consent

2. Histological confirmation of early stage (II-III) locally advanced or advanced ER positive and HER2 negative breast cancer

3. Tumor DNA sequencing has been completed by selected NGS vendor(s) at the time of or prior to treatment initiation

4. Female participants between 18 - 85 years of age

5. ECOG performance status that is equal to 0 or 1 at the time of screening.

6. Must be willing to provide blood for immune profile analysis on study enrollment and at specified study time points

7. Must be willing and able to perform stool sample collection

8. Participants due to receive standard of care CDK4/6 inhibitors (palbociclib, ribociclib, or abemaciclib) in combination with endocrine therapy

Exclusion Criteria:

Arm-1: Early stage (II-III), locally advanced or advanced ER-positive and HER2-negative Breast Cancer

1. Adult males

2. Mental incapacity, as determined by an investigator

3. Participant is pregnant, breastfeeding, or plans to become pregnant during the course of the study

4. Experiencing active brain metastasis/metastases

5. Active participation in an immuno-oncology or interventional clinical trial

6. Participation in any experimental trial in the 3 months prior to screening

7. Participant has relapsed on prior endocrine therapy for this instance of cancer, or has discontinued any prior adjuvant endocrine therapy within 6 months of screening

8. History of inflammatory bowel disease, chronic diarrhea or malabsorption syndromes, or significant prior bowel resection as judged by the study investigator

9. Use of immunosuppressants, including steroids, within 4 weeks of the first sample collection

10. Oral or intravenous antibiotic usage within 3 months of the first sample collection

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Other:
• Observation
No Intervention

Locations

Country	Name	City	State
United States	New Jersey Cancer Care, PA	Belleville	New Jersey
United States	Cancer Care Specialists of Illinois	Decatur	Illinois
United States	Valley Cancer Associates, PA	Harlingen	Texas
United States	Cayuga Medical Center	Ithaca	New York
United States	OptumCare Cancer Care	Las Vegas	Nevada
United States	Toledo Clinic Cancer Center	Toledo	Ohio

Sponsors (2)

Lead Sponsor	Collaborator
BioCorteX Inc	Tempus AI

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Interaction between the gut microbiome, tumor microbiome and serum immune profile for patients with early stage (II-III), locally advanced or advanced ER-positive and HER2-negative breast cancer.	Microbiome data obtained from fecal samples will be compared using alpha and beta diversity metrics.	Screening, week 2, week 4, week 6